Li Xu
Xi'an, 710032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The Clinical Application Value of Blood Lipid Levels in Multiple Myeloma.
Journal: Clinical laboratory
Published: January 16, 2026
Zalcitabine induces ferroptosis in multiple myeloma through the TFAM-cGAS-STING-SLC7A11 axis.
Journal: Journal of translational medicine
Published: September 28, 2025
BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis.
Journal: Therapeutic advances in hematology
Published: February 04, 2020
CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.
Journal: International journal of molecular medicine
Published: October 06, 2019
Synergistic Efficacy of the Demethylation Agent Decitabine in Combination With the Protease Inhibitor Bortezomib for Treating Multiple Myeloma Through the Wnt/β-Catenin Pathway.
Journal: Oncology research
Published: March 07, 2019
Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib.
Journal: Cell death & disease
Published: February 22, 2019
Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials.
Journal: Journal of immunology research
Published: March 14, 2018
Valproic Acid Represses Autophagy and Enhances the Anti-myeloma Activity of DNA-damaging Drugs
Journal: Zhongguo shi yan xue ye xue za zhi
Published: June 29, 2015
Inducing effect of chidamide on apoptosis of multiple myeloma cells and its relerance to DNA damage response
Journal: Zhongguo shi yan xue ye xue za zhi
Published: May 08, 2015
Showing 1-10 of 10
Last Updated: 09/26/2026